Guillaume Guimbretière, Clément Dubost, Justin Issard, Virginie Louvain-Quintard, Xavier Jais, Samuel Dolidon, François Stephan, Daniela-Iolanda Ion, Olaf Mercier, Elie Fadel
{"title":"肺血栓动脉内膜切除术中疑似肝素诱导的血小板减少:回顾性队列。","authors":"Guillaume Guimbretière, Clément Dubost, Justin Issard, Virginie Louvain-Quintard, Xavier Jais, Samuel Dolidon, François Stephan, Daniela-Iolanda Ion, Olaf Mercier, Elie Fadel","doi":"10.1093/icvts/ivaf001","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Heparin is given for anticoagulation during and after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Our objective was to add to the limited data available on the incidence, management and outcomes of suspected heparin-induced thrombocytopaenia after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension.</p><p><strong>Methods: </strong>This retrospective single-centre study included consecutive patients with suspected heparin-induced thrombocytopaenia after pulmonary thromboendarterectomy done in 2005-2018. Confirmed heparin-induced thrombocytopaenia was defined as positive findings from both the antibody test and the platelet aggregation test. Patients with versus without confirmed heparin-induced thrombocytopaenia were compared, as well as patients with versus without heparin replacement therapy within the group with unconfirmed heparin-induced thrombocytopaenia. The platelet counts over time were compared to those in controls without suspected heparin-induced thrombocytopaenia.</p><p><strong>Results: </strong>Heparin-induced thrombocytopaenia was suspected in 86 (6.3%) of 1360 patients and confirmed in 16 (16/86, 19%), all of whom received heparin replacement therapy and survived to intensive care unit discharge. Of the remaining 70 patients, 28 (40%) received heparin replacement therapy and less often experienced bleeding compared to the other 42 (3.6% vs 21.4%, P = 0.043). Intensive care unit mortality was 17/70 (24.3%) and was lower in the subgroup given heparin replacement therapy (10.7% vs 33.3%; P = 0.046). Confirmed heparin-induced thrombocytopaenia was associated with a sharp platelet-count drop on Day 5. In unconfirmed suspected heparin-induced thrombocytopaenia, the early platelet-count decline was similar to that in the controls without suspected heparin-induced thrombocytopaenia, but the baseline count was lower.</p><p><strong>Conclusions: </strong>Clinical features suggesting heparin-induced thrombocytopaenia after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension were associated with excess mortality. Relay heparin replacement therapy was associated with lower mortality and fewer bleeding events.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11754861/pdf/","citationCount":"0","resultStr":"{\"title\":\"Suspected heparin-induced thrombocytopaenia in pulmonary thromboendarterectomy: retrospective cohort.\",\"authors\":\"Guillaume Guimbretière, Clément Dubost, Justin Issard, Virginie Louvain-Quintard, Xavier Jais, Samuel Dolidon, François Stephan, Daniela-Iolanda Ion, Olaf Mercier, Elie Fadel\",\"doi\":\"10.1093/icvts/ivaf001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Heparin is given for anticoagulation during and after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Our objective was to add to the limited data available on the incidence, management and outcomes of suspected heparin-induced thrombocytopaenia after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension.</p><p><strong>Methods: </strong>This retrospective single-centre study included consecutive patients with suspected heparin-induced thrombocytopaenia after pulmonary thromboendarterectomy done in 2005-2018. Confirmed heparin-induced thrombocytopaenia was defined as positive findings from both the antibody test and the platelet aggregation test. Patients with versus without confirmed heparin-induced thrombocytopaenia were compared, as well as patients with versus without heparin replacement therapy within the group with unconfirmed heparin-induced thrombocytopaenia. The platelet counts over time were compared to those in controls without suspected heparin-induced thrombocytopaenia.</p><p><strong>Results: </strong>Heparin-induced thrombocytopaenia was suspected in 86 (6.3%) of 1360 patients and confirmed in 16 (16/86, 19%), all of whom received heparin replacement therapy and survived to intensive care unit discharge. Of the remaining 70 patients, 28 (40%) received heparin replacement therapy and less often experienced bleeding compared to the other 42 (3.6% vs 21.4%, P = 0.043). Intensive care unit mortality was 17/70 (24.3%) and was lower in the subgroup given heparin replacement therapy (10.7% vs 33.3%; P = 0.046). Confirmed heparin-induced thrombocytopaenia was associated with a sharp platelet-count drop on Day 5. In unconfirmed suspected heparin-induced thrombocytopaenia, the early platelet-count decline was similar to that in the controls without suspected heparin-induced thrombocytopaenia, but the baseline count was lower.</p><p><strong>Conclusions: </strong>Clinical features suggesting heparin-induced thrombocytopaenia after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension were associated with excess mortality. Relay heparin replacement therapy was associated with lower mortality and fewer bleeding events.</p>\",\"PeriodicalId\":73406,\"journal\":{\"name\":\"Interdisciplinary cardiovascular and thoracic surgery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11754861/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Interdisciplinary cardiovascular and thoracic surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/icvts/ivaf001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"0\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interdisciplinary cardiovascular and thoracic surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/icvts/ivaf001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
目的:肝素用于慢性血栓栓塞性肺动脉高压患者肺动脉内膜切除术期间和之后的抗凝治疗。我们的目的是增加现有的关于慢性血栓栓塞性肺动脉高压患者肺血栓动脉内膜切除术后疑似肝素诱导的血小板减少的发生率、管理和结果的有限数据。方法:本回顾性单中心研究纳入了2005-2018年肺血栓内膜切除术后疑似肝素诱导的血小板减少症患者。确认肝素诱导的血小板减少症被定义为抗体试验和血小板聚集试验的阳性结果。比较未确诊肝素诱导的血小板减少的vs患者,以及未确诊肝素诱导的血小板减少组中未接受肝素替代治疗的vs患者。随着时间的推移,血小板计数与没有肝素诱导的血小板减少症的对照组进行比较。结果:1360例患者中有86例(6.3%)怀疑肝素所致血小板减少症,16例(16/86,19%)确诊肝素所致血小板减少症,所有患者均接受肝素替代治疗,存活至重症监护病房出院。在其余70例患者中,28例(40%)接受了肝素替代治疗,与其他42例患者相比,出血较少(3.6%对21.4%,p = 0.043)。重症监护病房死亡率为17/70(24.3%),给予肝素替代治疗的亚组死亡率较低(10.7% vs 33.3%;p = 0.046)。证实肝素诱导的血小板减少与第5天血小板计数急剧下降有关。在未确诊的疑似肝素诱导的血小板减少中,早期血小板计数下降与未确诊肝素诱导的血小板减少的对照组相似,但基线计数较低。结论:临床特征提示慢性血栓栓塞性肺动脉高压患者肺动脉内膜切除术后肝素诱导的血小板减少与高死亡率相关。继发性肝素替代治疗与较低的死亡率和较少的出血事件相关。
Suspected heparin-induced thrombocytopaenia in pulmonary thromboendarterectomy: retrospective cohort.
Objectives: Heparin is given for anticoagulation during and after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Our objective was to add to the limited data available on the incidence, management and outcomes of suspected heparin-induced thrombocytopaenia after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension.
Methods: This retrospective single-centre study included consecutive patients with suspected heparin-induced thrombocytopaenia after pulmonary thromboendarterectomy done in 2005-2018. Confirmed heparin-induced thrombocytopaenia was defined as positive findings from both the antibody test and the platelet aggregation test. Patients with versus without confirmed heparin-induced thrombocytopaenia were compared, as well as patients with versus without heparin replacement therapy within the group with unconfirmed heparin-induced thrombocytopaenia. The platelet counts over time were compared to those in controls without suspected heparin-induced thrombocytopaenia.
Results: Heparin-induced thrombocytopaenia was suspected in 86 (6.3%) of 1360 patients and confirmed in 16 (16/86, 19%), all of whom received heparin replacement therapy and survived to intensive care unit discharge. Of the remaining 70 patients, 28 (40%) received heparin replacement therapy and less often experienced bleeding compared to the other 42 (3.6% vs 21.4%, P = 0.043). Intensive care unit mortality was 17/70 (24.3%) and was lower in the subgroup given heparin replacement therapy (10.7% vs 33.3%; P = 0.046). Confirmed heparin-induced thrombocytopaenia was associated with a sharp platelet-count drop on Day 5. In unconfirmed suspected heparin-induced thrombocytopaenia, the early platelet-count decline was similar to that in the controls without suspected heparin-induced thrombocytopaenia, but the baseline count was lower.
Conclusions: Clinical features suggesting heparin-induced thrombocytopaenia after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension were associated with excess mortality. Relay heparin replacement therapy was associated with lower mortality and fewer bleeding events.